Brace Pharma

Brace Pharma is a London-based corporate venture vehicle partnered with EMS S/A to fund the development of innovative therapies targeting severe diseases. The corporate VC structure shapes the firm’s behavior: capital is deployed with a strategic perspective informed by EMS’s pharmaceutical operations, and Brace looks for therapeutic assets that align with serious unmet need across pharma and biotech. Founders developing novel small molecules, biologics, or platform-driven programs are the natural fit. AI is not a stated focus.

Brace invests at Series A and Series B with checks of $5M to $25M, indicating that programs should be moving from preclinical proof of concept into clinical development or be positioned to advance through early clinical trials. The geographic mandate is global, with London providing reach into European biotech and the EMS connection extending engagement into Latin American markets where the parent operates. Founders should prepare for diligence that incorporates both financial venture criteria and strategic alignment considerations characteristic of corporate venture partners.

Named partners and a complete portfolio list are not provided in the materials reviewed, so this profile relies on limited public information about specific team composition and prior investments. Founders considering Brace Pharma should think carefully about how the EMS partnership affects long-term strategic optionality, including potential commercial collaborations, licensing pathways, and territorial development rights. The most useful first conversation explains the therapeutic rationale, the clinical development plan, and how the founders view a corporate-strategic investor’s role within the broader cap table and partnership landscape.